

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
24 September 2020 (24.09.2020)



(10) International Publication Number
WO 2020/187848 A1

(51) International Patent Classification:
C07K 14/55 (2006.01) A61P 35/00 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2020/057140

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:
16 March 2020 (16.03.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP2019/056719
18 March 2019 (18.03.2019) EP

(71) Applicant: **BIONTECH CELL & GENE THERAPIES
GMBH** [DE/DE]; An der Goldgrube 12, 55131 Mainz
(DE).

(72) Inventors: **SAHIN, Ugur**; c/o BioNTech SE, An der Gold-
grube 12, 55131 Mainz (DE). **FELLERMEIER-KOPF,
Sina**; c/o BioNTech SE, An der Goldgrube 12, 55131 Mainz
(DE). **MUIK, Alexander**; c/o BioNTech SE, An der Gold-
grube 12, 55131 Mainz (DE). **BIRTEL, Matthias**; c/o
BioNTech SE, An der Goldgrube 12, 55131 Mainz (DE).

(74) Agent: **SCHNAPPAUF, Georg**; Zwicker Schnappauf &
Partner Patentanwälte PartG mbB, Hansastr. 32, 80686 Mu-
nich (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: LINTERLEUKIN-2 RECEPTOR (IL2R) AND INTERLEUKIN-2 (IL2) VARIANTS FOR SPECIFIC ACTIVATION OF
IMMUNE EFFECTOR CELLS

(57) Abstract: The invention relates to variants of the alpha subunit of interleukin-2 receptor (IL2R) and interleukin-2 (IL2). In one
embodiment, the IL2 variants described herein have amino acid substitutions at the region of IL2 that contacts the alpha (α) subunit
of the heterotrimeric IL2 receptor complex, IL2R $\alpha\beta\gamma$, reducing its ability to bind and activate the heterotrimeric receptor complex.
Conversely, the corresponding IL2R α variants described herein have amino acid substitutions compensating for such reduced ability of
IL2 variants to bind to and activate IL2R $\alpha\beta\gamma$, preferably at amino acid residues contacted by IL2 amino acid residues that are substituted
in the IL2 variants described herein.



WO 2020/187848 A1